MedTrace Logo

Determining the Effect of Protein Quality on Post-exercise Anabolism in Active Youth

NCT05052827 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-11-13

No results posted yet for this study

Summary

Leucine-enriched proteins (e.g., dairy) are more effective than plant-based sources for supporting post-exercise rates of muscle protein synthesis in adults. However, the impact of protein quality on protein synthesis and acute markers of growth in active children are unknown. Using a randomized crossover design, the investigators will compare the effects of ingesting 0.35g/kg fat free mass (FFM) of either milk protein concentrate (MPC), rice protein isolate (RPI), or soy protein isolate (SPI) following a bout of variable intensity exercise with whole-body protein kinetics (i.e., oxidation, synthesis, breakdown, and net balance) determined by oral \[13C\]phenylalanine tracer methodology.

Conditions

  • Dietary Proteins

Interventions

DIETARY_SUPPLEMENT

Milk Protein Concentrate

Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below. Per 100 g protein powder: Calories (Cal): 363 Carbs (g): 5.60 Protein (g): 82.60 Fat (g): 1.12 Total BCAA (g): 15.67 Total EAA (g): 34.66 Total AA (g): 83.27

DIETARY_SUPPLEMENT

Rice Protein Isolate

Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below. Per 100 g protein powder: Calories (Cal): 394 Carbs (g): 6.50 Protein (g): 86.70 Fat (g): 2.39 Total BCAA (g): 14.98 Total EAA (g): 30.62 Total AA (g): 86.11

DIETARY_SUPPLEMENT

Soy Protein Isolate

Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below. Per 100 g protein powder: Calories (Cal): 377 Carbs (g): 2.12 Protein (g): 88.8 Fat (g): 0.60 Total BCAA (g): 13.88 Total EAA (g): 31.74 Total AA (g): 89.39

Sponsors & Collaborators

  • Dairy Management Inc.

    collaborator INDUSTRY

  • University of Toronto

    lead OTHER

Principal Investigators

  • Daniel Moore, PhD · University of Toronto

  • Hugo JW Fung, MSc · University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
8 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2023-12-31
Completion
2024-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05052827 on ClinicalTrials.gov